Possibilities of combined intranasal drugs in the treatment of patients with rhinosinusitis

Rhinosinusitis – an inflammatory process in the nasal cavity and paranasal sinuses is a global problem of practical medicine, which remains relevant for many years. The most common cause acute rhinosinusitis viral infection, only 0.2–5 % patients disease further complicated by formation bacterial focus inflammation. Treatment withARS involves use etiotropic, pathogenetic symptomatic therapy. National clinical guidelines consider systemic topical etiotropic drugs, intranasal glucocorticosteroids, decongestants, irrigation- elimination procedures, mucoactive therapy, standardized herbal drainage sinuses, antihistamines (with concomitant allergies) some other activities. Local administration drugs with provides targeted delivery active substance to pathological creation its required concentration, virtual absence action due low absorption, as well favorable softening, moisturizing, enveloping effect auxiliary components. One these combined spray containing tuaminoheptane sulfate acetylcysteine. effectiveness safety this combination has been demonstrated results fairly large amount research. mild sufficiently long vasoconstrictive sulfate, direct mucolytic, antioxidant anti-inflammatory effects acetylcysteine high determine therapeutic value children from 6 years age adult rhinitis rhinosinusitis.